Third Circuit: No Preliminary Injunction for Contract Breach Absent Non-Speculative, Practically Unquantifiable Harm—Market-Share Loss in Biologics Is Not Per Se Irreparable

3.1. Precedents Cited (and How They Shaped the Decision)

A. The governing injunction framework and “gateway” irreparable harm

• Winter v. Nat. Res. Def. Council, Inc., 555 U.S. 7 (2008): The opinion uses Winter to reinforce that preliminary injunctions require a rigorous, non-categorical showing; courts may not dilute the irreparable-harm requirement based on case type.
• Del. State Sportsmen's Ass'n v. Del. Dep't of Safety & Homeland Sec., 108 F.4th 194 (3d Cir. 2024): Cited for the extraordinary nature of preliminary injunctions and the principle that the first two factors (likelihood of success and irreparable harm) are “most critical,” with irreparable harm acting as a threshold.
• Siemens USA Holdings Inc. v. Geisenberger, 17 F.4th 393 (3d Cir. 2021): Quoted for the four-factor test.
• In re Revel AC, Inc., 802 F.3d 558 (3d Cir. 2015) and S.S. Body Armor I, Inc. v. Carter Ledyard & Milburn LLP, 927 F.3d 763 (3d Cir. 2019): Used to confirm the Third Circuit’s sliding-scale approach does not eliminate the requirement of some showing of irreparable harm even where success on the merits is strong.
• Adams v. Freedom Forge Corp., 204 F.3d 475 (3d Cir. 2000); Reilly v. City of Harrisburg, 858 F.3d 173 (3d Cir. 2017); Frank's GMC Truck Ctr., Inc. v. Gen. Motors Corp., 847 F.2d 100 (3d Cir. 1988): These anchor the default proposition that where money damages can compensate, irreparable harm is generally lacking.
• Boynes v. Limetree Bay Ventures LLC, 110 F.4th 604 (3d Cir. 2024): Cited for the requirement that irreparable harm be non-speculative.

B. Contract-specific irreparable harm and the “impracticable to ascertain” standard

• ECRI v. McGraw-Hill, Inc., 809 F.2d 223 (3d Cir. 1987): This is the opinion’s core contract-law injunction authority. It supplies the two situations where irreparable injury may be found in a contract case: (1) unique/special subject matter making damages inadequate; or (2) “special and practical features” making the legal measure of loss impossible to ascertain so damages are impracticable. The Third Circuit treated this framework as controlling and rejected Janssen’s attempt to lower the bar from “impracticable” to merely “difficult.”
• United States v. Winstar Corp., 518 U.S. 839 (1996) (plurality op.): Cited for the principle that in contract, “damages are always the default remedy,” underscoring why courts are reluctant to enjoin in contract disputes absent a compelling irreparable-harm showing.
• BP Chems. Ltd. v. Formosa Chem. & Fibre Corp., 229 F.3d 254 (3d Cir. 2000): Janssen invoked this for “difficult to calculate,” but the court confined BP Chemicals to injuries like reputation—intangible harms often hard to monetize—rather than lost sales/market share.
• Bennington Foods LLC v. St. Croix Renaissance Grp., LLP, 528 F.3d 176 (3d Cir. 2008): Used as a caution: plaintiffs in contract cases cannot convert monetary injury into irreparable harm by indirectly styling it as reputational harm.
• Instant Air Freight Co. v. C.F. Air Freight, Inc., 882 F.2d 797 (3d Cir. 1989): Cited to show severity can matter at the extremes—e.g., where a business may not survive to collect a later money judgment—but Janssen did not show an existential threat.

C. Market share, Lanham Act history, and rejection of categorical presumptions

• Novartis Consumer Health, Inc. v. Johnson & Johnson-Merck Consumer Pharmaceuticals Co., 290 F.3d 578 (3d Cir. 2002): Janssen relied heavily on the statement that “loss of market share constitutes irreparable harm,” but the court narrowed that language to its facts and context: (i) strong evidence of measurable market-share diversion already occurring, (ii) brand loyalty, and (iii) Lanham Act-era practices where presumptions of irreparable harm were often applied.
• Ferring Pharms., Inc. v. Watson Pharms., Inc., 765 F.3d 205 (3d Cir. 2014) and Kos Pharms., Inc. v. Andrx Corp., 369 F.3d 700 (3d Cir. 2004): The court used Ferring (and its discussion of earlier Lanham Act presumptions) to distinguish and limit reliance on Novartis, emphasizing that presumptions of irreparable harm do not extend beyond those contexts and were later disavowed even within Lanham Act claims.
• eBay Inc. v. MercExchange, L.L.C., 547 U.S. 388 (2006): Cited for rejecting categorical rules/presumptions of irreparable harm (there, in patent injunctions), providing a broader equitable principle.
• Groupe SEB United States, Inc. v. Euro-Pro Operating LLC, 774 F.3d 192 (3d Cir. 2014): Reinforces the required case-by-case approach to irreparable harm rather than categorical market-share rules.

D. Speculation, imminence, and the evidentiary burden

• Acierno v. New Castle Cnty., 40 F.3d 645 (3d Cir. 1994): The court relied on Acierno for the proposition that “more than a risk” is required and that non-precise quantification does not make harm irreparable.
• Inwood Lab'ys, Inc. v. Ives Lab'ys, Inc., 456 U.S. 844 (1982): Cited for the principle that ignoring evidence can be legal error; here, the District Court did not ignore Janssen’s leverage argument but rejected it as speculative.

E. Janssen’s additional out-of-circuit references and why they did not carry the day

• TEK Glob., S.R.L. v. Sealant Sys. Int'l, Inc., i4i Ltd. P'ship v. Microsoft Corp., Abbott Lab'ys v. Sandoz, Inc., Sanofi-Synthelabo v. Apotex, Inc.: The Third Circuit treated these as patent-case authorities (often arising from an era or doctrinal setting where presumptions were more common) and not controlling for a Third Circuit contract-based injunction request.
• Boardman v. Pac. Seafood Grp. and Collins Inkjet Corp. v. Eastman Kodak Co.: Distinguished as antitrust cases where market structure and share can be intertwined with the claim’s elements and remedial adequacy.
• Disney Enters., Inc. v. VidAngel, Inc., Brady v. Nat'l Football League, United States v. Colorado: Treated as contextually different and not establishing a rule that negotiating leverage alone satisfies the irreparable-harm prong.
• Nichia Corp. v. Everlight Ams., Inc. and SmartSky Networks, LLC v. Gogo Bus. Aviation, LLC: Used to underscore “but for” causation and the need for concrete evidence (e.g., price erosion), which Janssen declined to pursue and, in any event, could not clearly attribute to Quallent given other biosimilar entries.
• Abbott Laboratories v. Sandoz, Inc., 500 F. Supp. 2d 807 (N.D. Ill. 2007): Mentioned largely to contrast alleged extreme market collapse (90% loss). The Third Circuit emphasized the District Court did not adopt a numeric threshold; it simply found Janssen had not shown comparable catastrophic harm.

3.2. Legal Reasoning

The court’s reasoning proceeds in a disciplined sequence consistent with Third Circuit injunction doctrine:

1. Irreparable harm is indispensable even with likely success on the merits. The District Court found Janssen likely to succeed on breach-of-contract and implied covenant claims, but the Third Circuit emphasized that this does not relax the independent requirement of irreparable harm.
2. No categorical “market-share loss = irreparable harm” rule in contract cases. The court rejected Janssen’s effort to treat loss of market share in biologics as inherently irreparable. It confined Novartis Consumer Health, Inc. v. Johnson & Johnson-Merck Consumer Pharmaceuticals Co. to a Lanham Act setting with brand loyalty and then-prevailing presumptions, and further noted that categorical presumptions were undermined by eBay Inc. v. MercExchange, L.L.C. and Winter v. Nat. Res. Def. Council, Inc., and disavowed within the Third Circuit’s Lanham Act jurisprudence by Ferring Pharms., Inc. v. Watson Pharms., Inc..
3. The contract standard is “impracticable to ascertain,” not “hard to calculate.” Invoking ECRI v. McGraw-Hill, Inc., the court treated “impossible/incapable of calculation” as shorthand for whether damages are practically determinable. Lost sales and market share—unlike goodwill or reputation harms—typically remain compensable with money damages, even if the modeling is complex.
4. Speculation and imminence defeat irreparable harm. On negotiating leverage, the court credited the District Court’s factual assessment that the claimed harm was speculative and not shown to be imminent. The opinion stressed that preliminary relief requires a “clear showing” of an “actual and imminent” injury, not a theory about how leverage might be diminished.
5. Severity matters only at the extremes in contract cases. The court acknowledged situations like Instant Air Freight Co. v. C.F. Air Freight, Inc., where the plaintiff might not survive to collect damages. But Janssen—given the scale of Stelara revenues and broader business context—did not establish this kind of existential risk from a short-term market shift.

Operative rule clarified: In a breach-of-contract case, alleged losses from market share, market dynamics, or negotiating leverage do not constitute irreparable harm absent a non-speculative, imminent showing that monetary damages would be impracticable to ascertain or otherwise inadequate under ECRI v. McGraw-Hill, Inc..

3.3. Impact

• Higher evidentiary burden for contract-based injunctions in life-sciences commercialization disputes. Even in markets characterized by “patent thickets,” regulated substitution dynamics, PBM formulary steering, and vertically integrated distribution, the Third Circuit signals that plaintiffs must do more than assert structural complexity. They must connect the alleged breach to concrete, imminent, non-monetizable harm.
• Limits on using “market complexity” to transform damages into irreparable harm. Parties negotiating settlement agreements and licenses in biologics may try to draft for injunctive triggers or liquidated damages mechanisms; absent such provisions, courts in this circuit will default to the view that lost sales and share are generally compensable.
• “Negotiating leverage” as harm remains disfavored unless supported by specific, near-term evidence. The opinion suggests that leverage-based theories need contemporaneous proof (e.g., imminent formulary removal, executed purchasing commitments, or documented negotiation demands tied to the challenged conduct), not generalized “playbook” descriptions.
• Reinforcement of post-eBay/Winter skepticism toward categorical presumptions. The court’s treatment of Novartis Consumer Health, Inc. v. Johnson & Johnson-Merck Consumer Pharmaceuticals Co.—as fact- and context-bound rather than a portable rule— further cabins attempts to import older “market share = irreparable” language into modern equitable analysis, especially outside the Lanham Act setting.